Last reviewed · How we verify

Broad Area ALA 2 hour incubation

DUSA Pharmaceuticals, Inc. · Phase 2 active Small molecule

Broad Area ALA 2 hour incubation is a Photodynamic therapy agent Small molecule drug developed by DUSA Pharmaceuticals, Inc.. It is currently in Phase 2 development for Actinic keratosis. Also known as: Levulan.

ALA (5-aminolevulinic acid) is a precursor to porphyrins, which accumulate in abnormal cells and become fluorescent under blue light, allowing for photodynamic therapy.

ALA (5-aminolevulinic acid) is a precursor to porphyrins, which accumulate in abnormal cells and become fluorescent under blue light, allowing for photodynamic therapy. Used for Actinic keratosis.

At a glance

Generic nameBroad Area ALA 2 hour incubation
Also known asLevulan
SponsorDUSA Pharmaceuticals, Inc.
Drug classPhotodynamic therapy agent
ModalitySmall molecule
Therapeutic areaDermatology
PhasePhase 2

Mechanism of action

This mechanism is based on the principle that abnormal cells, such as those found in actinic keratoses, will accumulate more porphyrins than normal cells. When exposed to blue light, these porphyrins become excited and release energy as heat, damaging the abnormal cells.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Broad Area ALA 2 hour incubation

What is Broad Area ALA 2 hour incubation?

Broad Area ALA 2 hour incubation is a Photodynamic therapy agent drug developed by DUSA Pharmaceuticals, Inc., indicated for Actinic keratosis.

How does Broad Area ALA 2 hour incubation work?

ALA (5-aminolevulinic acid) is a precursor to porphyrins, which accumulate in abnormal cells and become fluorescent under blue light, allowing for photodynamic therapy.

What is Broad Area ALA 2 hour incubation used for?

Broad Area ALA 2 hour incubation is indicated for Actinic keratosis.

Who makes Broad Area ALA 2 hour incubation?

Broad Area ALA 2 hour incubation is developed by DUSA Pharmaceuticals, Inc. (see full DUSA Pharmaceuticals, Inc. pipeline at /company/dusa-pharmaceuticals-inc).

Is Broad Area ALA 2 hour incubation also known as anything else?

Broad Area ALA 2 hour incubation is also known as Levulan.

What drug class is Broad Area ALA 2 hour incubation in?

Broad Area ALA 2 hour incubation belongs to the Photodynamic therapy agent class. See all Photodynamic therapy agent drugs at /class/photodynamic-therapy-agent.

What development phase is Broad Area ALA 2 hour incubation in?

Broad Area ALA 2 hour incubation is in Phase 2.

What are the side effects of Broad Area ALA 2 hour incubation?

Common side effects of Broad Area ALA 2 hour incubation include Skin irritation.

Related